Carfilzomib, lenalidomide, and dexamethasone (KRd) as maintenance therapy after autologous stem-cell transplantation (ASCT) in patients with newly diagnosed multiple myeloma (NDMM).
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Andrzej J. Jakubowiak, Tomasz Wrobel, Krzysztof Jamroziak, Tadeusz Kubicki, Pawel Robak, Jaroslaw Czyz, Agata Tyczyńska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Anna Łojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Puła, Justyna Rybka, Lidia Usnarska-Zubkiewicz, Olga Czabak, Anna Ewa Pula, Benjamin Avi Derman, Theodore Karrison, Dominik Dytfeld
Institutions: University of Chicago, Wroclaw Medical University, Instytut Hematologii i Transfuzjologi, Poznan University of Medical Sciences, Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Gdańsk Medical University, The Maria Sklodowska-Curie National Research Institute of Oncology, Medical University of Lublin, University of Chicago Medical Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Amgen
OpenAlex ID: W4410810025